Clinical Trials Logo

Chronic Bronchitis clinical trials

View clinical trials related to Chronic Bronchitis.

Filter by:

NCT ID: NCT04636801 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)

PILASTER
Start date: July 14, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of two doses of CHF6001 (Tanimilast), as add-on to maintenance triple therapy in the target patient population.

NCT ID: NCT04631016 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

FRONTIER-4
Start date: December 14, 2020
Phase: Phase 2
Study type: Interventional

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.

NCT ID: NCT04613180 Active, not recruiting - Acute Bronchiolitis Clinical Trials

Evaluation of the Effectiveness of Montelukast in Children With Recurrent Obstructive Bronchitis

Start date: January 3, 2018
Phase: Phase 4
Study type: Interventional

The aim of the study was to evaluate the effectiveness of montelukast sodium in the treatment and prevention of recurrent obstructive bronchitis in children. The investigators examined 80 children aged 1 to 7 years with recurrent obstructive bronchitis, who were randomly divided into 2 groups.

NCT ID: NCT04505202 Completed - Clinical trials for Ventilator Associated Pneumonia

Effect of Chlorhexidine-Induced Oral Care on Ventilator-Related Some Respiratory System Complications

Start date: April 15, 2019
Phase: N/A
Study type: Interventional

Ventilator-associated pneumonia and ventilator-associated treakeabronchitis in respiratory tract infections associated with ventilator are common infections in intensive care unit and cause significant morbidity, mortality and health expenditures in nosocomial infections. Adequate and effective oral care by nurses in intensive care patients, possible complications, intensive care unit stay in the intensive care unit and is very important in terms of mortality.

NCT ID: NCT04441788 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)

Start date: December 22, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the effect of ION-827359 on forced expiratory volume in 1 second (FEV1) in participants with mild to moderate COPD with CB.

NCT ID: NCT04415827 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Energy Supply in Athletes and Untrained Persons With Bronchopulmonary Diseases

Start date: May 23, 2020
Phase: N/A
Study type: Interventional

Study of the energy supply of bicycle ergometric load in athletes and untrained persons with bronchopulmonary diseases (community-acquired pneumonia, bronchitis, chronic obstructive pulmonary disease and acute respiratory viral infections, to justify the timing of the resumption of training, as well as determination of the volume and intensity of physical activity in training and competitive processes.

NCT ID: NCT04378231 Not yet recruiting - Clinical trials for Protracted Bacterial Bronchitis

Higher Versus Standard Dose of Amoxicillin-clavulanate in Pediatric PBB

Start date: May 2020
Phase: N/A
Study type: Interventional

Chronic wet cough is one of the most common symptoms of respiratory diseases in children. Protracted bacterial bronchitis (protracted bacterial bronchitis, PBB) is the most common cause of chronic wet cough in children. Potassium amoxicillin clavulanate is the recommended drug for the treatment of PBB, but there is not enough evidence to date on the dose and course of treatment. investigate the efficacy of different doses of amoxicillin clavulanate sodium in the treatment of chronic bacterial bronchitis in children. The methods of this study are summarized as following: 1. Screening cases of chronic wet cough in children aged 2 to 6 years old who came to our hospital for treatment. Those diagnosed as PBB were included in this study, after obtaining the written informed consent from their parents or guardians. 2. The enrolled patients were randomly divided into high-dose (90mg/kg/d) and standard dose (60mg/kg/d) amoxicillin clavulanate potassium treatment group. 3. Medical history data of enrolled patients and daily cough score data were collected. 4. Assess the cough remission rate within two weeks and recurrence rate within 6 months in both groups.

NCT ID: NCT04260555 Active, not recruiting - Acute Bronchitis Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of 'DW1601' in Acute Bronchitis

Start date: December 20, 2018
Phase: Phase 3
Study type: Interventional

A Multicenter, Randomized, Double-Blind, Parallel, Active-controlled, Superiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW1601 Compared to DW16011 and DW16012 for Acute Bronchitis

NCT ID: NCT04252963 Recruiting - Acute Bronchitis Clinical Trials

Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)

Start date: November 2, 2018
Phase: Phase 4
Study type: Interventional

A phase 4 study to evaluate efficacy and safety of MUCOLASE tablet (streptokinase • streptodornase)

NCT ID: NCT04239521 Completed - Asthma Clinical Trials

The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata

Start date: October 1, 2020
Phase:
Study type: Observational

This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and incidence of psychiatric co-morbidities in people with alopecia areata, (3) the prevalence and incidence of autoimmune and atopic conditions in people with alopecia areata, and (4) the incidence of common infections in people with alopecia areata.